Neogenomics, Inc.
NEO
$10.10
$0.323.27%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 709.16M | 689.19M | 672.36M | 660.57M | 644.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 709.16M | 689.19M | 672.36M | 660.57M | 644.12M |
| Cost of Revenue | 401.36M | 386.95M | 374.48M | 370.47M | 363.69M |
| Gross Profit | 307.81M | 302.24M | 297.88M | 290.10M | 280.43M |
| SG&A Expenses | 362.48M | 353.17M | 340.39M | 335.52M | 327.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 799.70M | 774.97M | 748.59M | 737.14M | 721.96M |
| Operating Income | -90.54M | -85.78M | -76.23M | -76.58M | -77.84M |
| Income Before Tax | -113.99M | -105.45M | -78.65M | -80.68M | -79.83M |
| Income Tax Expenses | -522.00K | -1.41M | -1.06M | -1.95M | -2.11M |
| Earnings from Continuing Operations | -113.47 | -104.04 | -77.59 | -78.73 | -77.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -113.47M | -104.04M | -77.59M | -78.73M | -77.73M |
| EBIT | -90.54M | -85.78M | -76.23M | -76.58M | -77.84M |
| EBITDA | -20.92M | -14.62M | -4.22M | -4.03M | -5.12M |
| EPS Basic | -0.89 | -0.82 | -0.61 | -0.62 | -0.62 |
| Normalized Basic EPS | -0.41 | -0.37 | -0.32 | -0.32 | -0.32 |
| EPS Diluted | -0.89 | -0.82 | -0.61 | -0.63 | -0.62 |
| Normalized Diluted EPS | -0.41 | -0.37 | -0.32 | -0.32 | -0.32 |
| Average Basic Shares Outstanding | 510.90M | 509.44M | 507.89M | 506.63M | 505.40M |
| Average Diluted Shares Outstanding | 510.90M | 509.44M | 507.89M | 506.63M | 505.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |